Specialised Therapeutics Expands Opzelura Partnership in Australia
Singapore, September 21, 2026 Specialised Therapeutics (ST) has expanded its existing partnership with Incyte to include ruxolitinib cream (Opzelura®)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Singapore, September 21, 2026 Specialised Therapeutics (ST) has expanded its existing partnership with Incyte to include ruxolitinib cream (Opzelura®)...
New York, New York, U.S., September 10, 2026 Breakthrough T1D has announced the publication of new international consensus guidance...
Taipei, Taiwan, September 11, 2026 Avance Clinical has received the Australia-Taiwan Business Excellence Award from the Australia New Zealand...
Tokyo, Japan, August 25, 2026 Astellas Pharma Inc. announced that the first patient has been dosed in a Phase...
Shanghai and Hong Kong, China, August 25, 2026 Antengene Corporation Limited announced that the Phase I ATTRACT clinical study...
MELBOURNE, Australia & INDIANAPOLIS, Ind., July 16, 2026 Telix has officially opened Telix Manufacturing Solutions North Melbourne (TMSNM), Australia’s...
SHANGHAI, China, July 13, 2026 Delonix Bioworks, a clinical-stage biotechnology company specializing in genetically engineered bacterial vaccines, has announced...
SAN DIEGO & MELBOURNE, Australia, June 24, 2026 LENZ Therapeutics has significantly expanded the international commercialization strategy for its...
